MARS: mutation-adjusted risk score for advanced systemic mastocytosis
0 Views
administrator
07/09/23
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
-
Category
Show more
Facebook Comments
No comments found